Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (61-70 of 224) with videos related to

Pageof 23
Sort By:
Haematologica|May 30, 2024
The phase III DUO trial of PI3K inhibitor duvelisib <i>versus</i> ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survivalAlexey V Danilov, Ian W Flinn, Matthew S Davids, et al.
European Journal of Heart Failure|May 10, 2017
Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemiaDavid D Berg, Muthiah Vaduganathan, Anju Nohria, et al.
Pharmacoeconomics - Open|September 30, 2020
Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell LymphomaNeerav Monga, Jamie Garside, Matthew S Davids, et al.
Advances in Hematology|December 29, 2025
Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment PatternsCsaba Siffel, Matthew S Davids, Colin Anderson-Smits, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Sheila Shapouri, Beenish S Manzoor, et al.
Current Medical Research and Opinion|March 13, 2020
Systematic literature review of the global burden of illness of mantle cell lymphomaNeerav Monga, Jamie Garside, Joan Quigley, et al.
American Journal of Hematology|December 20, 2021
A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemiaMatthew S Davids, Mazyar Shadman, Sameer A Parikh, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 11, 2024
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell MalignancyJoshua Richter, Matthew S Davids, Colin Anderson-Smits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2015
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaJennifer R Brown, Matthew S Davids, Jordi Rodon, et al.
BJR Case Reports|October 27, 2018
Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd coupleAnn C Raldow, Johann G Brown, Nicole Chau, et al.
Pageof 23

Showing results (61-70 of 224) with videos related to

Sort By:
Pageof 23
Haematologica|May 30, 2024
The phase III DUO trial of PI3K inhibitor duvelisib <i>versus</i> ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survivalAlexey V Danilov, Ian W Flinn, Matthew S Davids, et al.
European Journal of Heart Failure|May 10, 2017
Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemiaDavid D Berg, Muthiah Vaduganathan, Anju Nohria, et al.
Pharmacoeconomics - Open|September 30, 2020
Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell LymphomaNeerav Monga, Jamie Garside, Matthew S Davids, et al.
Advances in Hematology|December 29, 2025
Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment PatternsCsaba Siffel, Matthew S Davids, Colin Anderson-Smits, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Sheila Shapouri, Beenish S Manzoor, et al.
Current Medical Research and Opinion|March 13, 2020
Systematic literature review of the global burden of illness of mantle cell lymphomaNeerav Monga, Jamie Garside, Joan Quigley, et al.
American Journal of Hematology|December 20, 2021
A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemiaMatthew S Davids, Mazyar Shadman, Sameer A Parikh, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 11, 2024
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell MalignancyJoshua Richter, Matthew S Davids, Colin Anderson-Smits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2015
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaJennifer R Brown, Matthew S Davids, Jordi Rodon, et al.
BJR Case Reports|October 27, 2018
Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd coupleAnn C Raldow, Johann G Brown, Nicole Chau, et al.
Pageof 23